Perspectives in adjuvant therapy of gastric cancer

Oncology

Volumn 77, Issue SUPPL. 1, 2010, Pages 38-42

  De Vita, Ferdinando ^a   Vecchione, Loredana ^a   Galizia, Gennaro ^a   Di Martino, Natale ^a   Fabozzi, Teresa ^a   Catalano, Giuseppe ^a   Ciardiello, Fortunato ^a   Orditura, Michele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Adjuvant chemotherapy; Anti EGFR drugs; Chemoradiotherapy

Indexed keywords

ANGIOGENESIS INHIBITOR; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISTANT METASTASIS; DRUG EFFICACY; GASTRECTOMY; HUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURGICAL TECHNIQUE; SURVIVAL RATE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; DRUG ANTAGONISM; MULTIMODALITY CANCER THERAPY; PROGNOSIS; STOMACH TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; GASTRECTOMY; HUMANS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 77949910448     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000258494     Document Type: Review

References (44)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
2. Levi F, Lucchini F, Negri E, et al: Cancer mortality in Europe,1995-1999, and an overview of trends since 1960. Int J Cancer 2004; 110: 155-169.
3. Levi F, Lucchini F, Gonzalez JR, et al: Monitoring falls in gastric cancer mortality in Europe. Ann Oncol 2004; 15: 338-345. (Pubitemid 38262637)
4. Hartgrink HH, Bonekamp HJ, van de Velde CJ: Influence of surgery on outcomes in gastric cancer. Surg Oncol Clin N Am 2000; 9: 91-117.
5. Takagane A, Terashima M, Abe K, et al: Evaluation of the ratio of the lymph nodes metastasis as a prognostic factor in patients with gastric cancer. Gastric Cancer 1999; 2: 122-128.
6. Arak A, Kull K: Factors influencing survival of patients after radical surgery for gastric cancer. Ann Oncol 1994; 33: 913-920.
7. D'Ugo D, Rausei S, Biondi A, Persiani R: Preoperative treatment and surgery in gastric cancer. Lancet Oncol 2009; 10: 191-195.
8. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
9. Boige V, Pignon J, Saint-Aubert B, et al: Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 2007; 25(suppl):abstract 4510.
10. Schuhmacher C, Schlag P, Lordick F, et al: Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: randomized EORTC phase III trial 40954. J Clin Oncol 2009; 27(suppl):abstract 4510.
11. Roth AD: Curative treatment of gastric cancer: towards a multidisciplinary approach? Crit Rev Oncol Hematol 2003; 46: 59-100.
12. Bajetta E, Buzzoni R, Mariani L, et al: Adjuvant chemotherapy in gastric cancer: 5-year results of a randomized study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002; 13: 299-307.
13. De Vita F, Giuliani F, Orditura M, et al: Adjuvant chemotherapy with ELFE regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM). Ann Oncol 2007; 18: 1354-1358.
14. Cascinu S, Labianca R, Barone C, et al: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 2007; 99: 601-607. (Pubitemid 47073541)
15. Di Costanzo F, Gasperoni S, Manzione L, et al: Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 2008; 100: 388-398.
16. Hermans J, Bonekamp JJ, Bon MC, et al: Adjuvant therapy after resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11: 1441-1447.
17. Piedbois P, Buyse M: Meta-analyses need time, collaboration and funding. J Clin Oncol 1994; 12: 878-879.
18. Pignon, JP, Ducruex M, Rouger P: Metaanalysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. J Clin Oncol 1994; 12: 877-878.
19. Hermans J, Bonekamp H: In reply (letter). J Clin Oncol 1994; 12: 879-880.
20. Earle CC, Maroun JA: Adjuvant chemotherapy after resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. Eur J Cancer 1999; 35: 1059-1064.
21. Mari M, Floriani I, Tinazzi A, et al: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis for published randomized trials. A study of the GISCAD ( Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente ). Ann Oncol 2000; 11: 837-843.
22. Pansini I, Gianni L, Fattori PP, et al: Adjuvant chemotherapy in gastric cancer: a metaanalysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002; 88: 21-27.
23. Janunger KG, Hafstrom L, Glimelius B: Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002; 168: 597-608.
24. Buyse ME, Pignon J: Meta-analyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy and prognostic factors in gastric cancer. J Clin Oncol 2009; 27(suppl):abstract 4539.
25. Kaptain S, Tan LK, Chen B: Her-2/neu and breast cancer. Diagn Mol Pathol 2001; 10: 139-152.
26. Yano T, Ochiai A, Doi T, et al: Expression of HER2 in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit. J Clin Oncol 2004; 22:abstract 4053.
27. Lordick F, Bang YJ, Kang YK, et al: HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer. Eur J Cancer 2007; 5:abstract 3541.
28. Gravalos C, Márquez A, García-Carbonero R, et al: Correlation between Her2/ neu overexpression/ amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study. Gastrointestinal Cancers Symposium 2007; 130:abstract 89.
29. Kang Y, Bang Y, Lordick F, et al: Incidence of gastric and gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity. Gastrointestinal Cancers Symposium 2008; 75:abstract 11.
30. Tanner M, Hollmen M, Junttila TT, et al: Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16: 273-1227
31. Tateishi M, Toda T, Minamisono Y, et al: Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. Surg Oncol 1992; 49: 209-212.
32. Sasano H, Date F, Imatani A, et al: Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 1993; 24: 584-589.
33. Uchino S, Tsuda H, Maruyama K, et al: Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 1993; 72: 3179-3184.
34. Mizutani T, Onda M, Tokunaga A, et al: Relationship of c-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993; 72: 2083-2088.
35. Nakajima M, Sawada H, Yamada Y, et al: The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer 1999; 85: 1894-1902.
36. Park DI, Yun JW, Park JH, et al: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371-1379.
37. Matsui Y, Inomata M, Tojigamori M, et al: Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 2005; 27: 681-685.
38. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al: Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007; 59: 795-805.
39. Kim SY, Kim HP, Kim YJ, et al: Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008; 32: 89-95.
40. Van Cutsem E, Kang Y, Chung H, et al: Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009; 27(suppl):abstract 4509.
41. D'Angelica M, Gonen M, Brennan MF, et al: Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004; 240: 808-816.
42. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001 345: 725-730.
43. Macdonald JS, Benedetti J, Smalley S, et al: Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 2009; 27(suppl):abstract 4515.
44. Kim S, Lim DH, Lee J, et al: An observational study suggesting a clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 63: 1279-1285.